The Therapeutic Potential of Pristimerin in Osteoarthritis: Mechanistic Insights from in vitro and in vivo Studies
Li Yin,Yong Fan,Xugang Zhong,Xiang Meng,Zeju He,Zheping Hong,Jihang Chen,Qiong Zhang,Mingxiang Kong,Jiao Wang,Yu Tong,Qing Bi
DOI: https://doi.org/10.2147/dddt.s490388
IF: 4.3188
2024-11-28
Drug Design Development and Therapy
Abstract:Li Yin, 1– 4, &ast Yong Fan, 1– 4, &ast Xugang Zhong, 1, 3, 4 Xiang Meng, 1, 3, 4 Zeju He, 1, 3, 4 Zheping Hong, 1, 3, 4 Jihang Chen, 1, 3, 4 Qiong Zhang, 5 Mingxiang Kong, 1, 3, 4 Jiao Wang, 1, 3, 4 Yu Tong, 1, 3, 4 Qing Bi 1– 4 1 Department of Sports Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, 310000, People's Republic of China; 2 Postgraduate Training Base Alliance of Wenzhou Medical University, Wenzhou, Zhejiang Province, 325000, People's Republic of China; 3 Center for Rehabilitation Medicine, Department of Orthopedics, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, 310000, People's Republic of China; 4 Institute of Sports Medicine and Osteoarthropathy of Hangzhou Medical College, Hangzhou, Zhejiang, 310000, People's Republic of China; 5 Department of Nursing, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, 310000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yu Tong; Qing Bi, Department of Sports Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, 310000, People's Republic of China, Email ; Objective: Osteoarthritis (OA), a degenerative disease marked by cartilage erosion and synovial proliferation, has led to an increased interest in natural plant-based compounds to slow its progression. Pristimerin(Pri), a triterpenoid compound derived from Tripterygium wilfordii, has demonstrated anti-inflammatory and antioxidant characteristics. This study explores the protective effects of Pri on OA and its potential mechanisms. Methods: In this study, we examined the impact of Pri on the expression of inflammatory factors and extracellular matrix(ECM) degradation induced by IL-1β in chondrocyte experiments. Bioinformatics analysis was then performed to investigate the potential signaling pathways involved in Pri's protective effects. Finally, the efficacy of Pri in reducing cartilage degradation was further evaluated in a destabilization of the medial meniscus (DMM) mouse model. Results: Utilizing bioinformatics analysis and in vitro studies, it was revealed that Pri inhibits the activation of NF-κB and MAPK signaling pathways, leading to the reversal of upregulated MMP-13 (matrix metalloproteinases-13), iNOS (inducible nitric oxide synthase), and COX-2(cyclooxygenase-2) elicited by IL-1β stimulation, as well as the partial restoration of Collagen-II levels. Furthermore, in a DMM mouse model, the group treated with Pri exhibited reduced cartilage degradation and slowed OA progression compared to the modeling group. Conclusion: This research highlights Pri as a potential therapeutic agent for delaying OA progression. Keywords: pristimerin, MAPK/NF-κB, chondrocyte inflammation, cartilage protection, osteoarthritis, RNA transcriptome sequencing OA is a prevalent condition that affects joints, marked by the progressive deterioration of cartilage within the joint, alterations in the underlying bone structure, and the formation of bony outgrowths. 1,2 The incidence of OA exhibits a consistent increase with advancing age, significantly influencing the health status of individuals and emerging as a primary reason for disability within the elderly demographic. 3 This condition commonly appears due to gradual joint degeneration over time, resulting in stiffness, pain, and decreased mobility. 4 These symptoms are more common in weight-bearing joints. 5,6 In advanced stages, OA can also cause significant joint swelling and deformity. 7 These clinical manifestations highlight the complexity of this degenerative joint disorder and emphasize its multifaceted impact on patients' health. 8–10 Recent research has indicated that the upregulation of inflammatory factor expression is an integral part of the development of OA. 11,12 It's worth noting that excessive expression of IL-1β significantly accelerates the progression of OA. 13 Specifically, the elevated secretion initiates the generation and discharge of inflammatory agents and catabolic elements, such as cyclooxygenase-2 (COX-2), matrix metalloproteinases-13 (MMP-13), and inducible nitric -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal